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Abstract
Background: Electrical pulses have been used to enhance uptake of molecules into living cells for decades. This technique,
often referred to as electroporation, has become an increasingly popular method to enhance in vivo DNA delivery for both
gene therapy applications as well as for delivery of vaccines against both infectious diseases and cancer. In vivo
electrovaccination (gene delivery followed by electroporation) is currently being investigated in several clinical trials,
including DNA delivery to healthy volunteers. However, the mode of action at molecular level is not yet fully understood.
Methodology/Principal Findings: This study investigates intradermal DNA electrovaccination in detail and describes the
effects on expression of the vaccine antigen, plasmid persistence and the local tissue environment. Gene profiling of the
vaccination site showed that the combination of DNA and electroporation induced a significant up-regulation of pro-
inflammatory genes. In vivo imaging of luciferase activity after electrovaccination demonstrated a rapid onset (minutes) and
a long duration (months) of transgene expression. However, when the more immunogenic prostate specific antigen (PSA)
was co-administered, PSA-specific T cells were induced and concurrently the luciferase expression became undetectable.
Electroporation did not affect the long-term persistence of the PSA-expressing plasmid.
Conclusions/Significance: This study provides important insights to how DNA delivery by intradermal electrovaccination
affects the local immunological responses of the skin, transgene expression and clearance of the plasmid. As the described
vaccination approach is currently being evaluated in clinical trials, the data provided will be of high significance.
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Introduction
Numerous strategies – physical, chemical and immunological –
are under investigation to improve the efficacy of DNA vaccines
(reviewed in [1,2]). In vivo electroporation devices have proven to be
effective tools for enhanced delivery of DNA to muscle, skin and
tumors. A wide range of studies have demonstrated that using
electroporative DNA administration in small [3,4] as well as large
[5,6] animals greatly increases gene expression and also induces
impressive immune responses. The first gene therapy product with
delivery by electroporation was licensed in 2007 in Australia for use
in swine [1]. Several clinical investigations of intramuscular DNA
delivery by electroporation have been under way since 2004 [7] and
a number of new clinical investigations of both intramuscular and
intradermal electroporation are in the pipeline. Results from the
first clinical study of intratumoral electroporative DNA delivery
recently demonstrated that in vivo electroporation is safe, effective
and reproducible in patients with metastatic melanoma [8].
Pre-clinical electrovaccination (gene delivery followed by
electroporation) studies performed to investigate the effect of
electroporation on antigen expression kinetics [4,9,10], DNA
persistence [11–13], local tissue injury, inflammation and cellular
infiltration [12,14] have generally utilized intramuscular DNA
delivery and electroporation. Since electroporation increases
transgene expression 10-100-fold [9,10,15,16], probably due to a
higher cellular uptake of DNA molecules, safety-related questions
have been raised about the possibility that electroporation could
lead to increased DNA persistence and a higher integration
frequency [7,17]. Results from studies of intramuscular electro-
poration are inconclusive, showing both increased integration
[13], unchanged persistence of DNA in tissue [11,12] and
decreased levels of plasmid associated with high molecular
genomic DNA [11]. However, to our knowledge, no data have
been published on plasmid persistence or integration after skin
electroporation. Furthermore, it has been suggested that intra-
muscular electroporation has adjuvant-like properties, such as
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cellular infiltration and moderate tissue injury [18–20]. Although
both cellular infiltration and tissue damage have been indicated
after skin electroporation [21], there is a lack of data both on the
effect of the local tissue environment at the molecular level and on
the possibility of an adjuvant effect.
Skin electroporation of genetic vaccines has shown very
promising immune responses in small [16,22,23] and large animal
models [21,24] and is a very attractive DNA delivery method for
clinical use. Skin is an ideal target for DNA vaccine delivery, as it
is rich in antigen-presenting cells, such as Langerhans’ cells and
dermal dendritic cells. It also allows uncomplicated monitoring of
the vaccination area. Skin electroporation permits topical
application of a local anesthetic and uses short electrode needles.
This is expected to significantly improve the tolerability of vaccine
delivery compared to intramuscular electroporation, especially as
the electrodes will not stimulate nearly as much muscle
contraction. The effects of electrovaccination in the skin need to
be delineated with the same vigilance as for intramuscular
electroporation.
This study investigates the functional properties of intradermal
electroporative DNA delivery. It has evaluated the kinetics of
transgene expression after DNA injection, the location of
transfected cells in the skin, the effect on the local tissue
environment and the persistence of DNA molecules at the
injection site.
Results
Intradermal DNA electroporation results in rapid, high
and stable transgene expression, predominantly in the
hypodermis
The impact of electroporation on transgene expression after
intradermal DNA delivery was investigated. Mice received intra-
dermal injections of 10 mg luciferase encoding plasmid and half of
them were subjected to electroporation. Luciferase expression was
measured using an in vivo imaging system. Mice receiving DNA in
combination with electroporation expressed luciferase already after
1h r( Fig. 1a), while expression in the non-electroporated mice was
below the detection level (,100 pixels/sec/cm
2). Luciferase expres-
sion in the electroporated mice was more stable and the average
emission was up to 2 logs higher than in the non-electroporated
mice. Average protein expression in the electroporated group
remained significantly higher until day 15 compared to the non-
electroporated mice (Fig. 1a). In a longer follow-up study, an
average level of 10
6 pixels/sec/cm
2 of luminescence was detected 5
Figure 1. Time kinetics of transgene expression in skin after DNA electrovaccination. (a) Time course of in vivo luciferase expression after
intradermal (i.d.) DNA delivery alone (dotted line) and after i.d. DNA delivery followed by electroporation (filled line). One representative experiment
of two is shown (n=8). (b–d) Immediate monitoring of gene expression after DNA electrovaccination. Representative bioluminescent images
showing luciferase expression in skin at different time points after DNA electrovaccination. N denotes the negative control (non-injected). The scale
shows intensity of luminescence (photons/sec/cm
2). The experiment was repeated three times.
doi:10.1371/journal.pone.0007226.g001
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shown). After the observation that electrovaccinated mice had
detectable luciferase expression already 1 hr after vaccination
(Fig. 1a) the early kinetics of luciferase gene expression after
electrovaccination was investigated in greater detail. Bioluminescent
images showed that the luciferase gene was expressed as early as 17
minutes after DNA injection (Fig. 1b). At 22 minutes post injection,
3 out of 4 injection sites expressed the luciferase gene (Fig. 1c)a n d
all sites did so after 30 minutes (Fig. 1d).
As in vivo monitoring of luciferase expression does not show
individual cells and the light emission spreads beyond the location
of transfected cells, histochemical staining of b-galactosidase was
used to investigate the location of the DNA transfected cells in the
skin. This demonstrated that the use of needle array electrodes
produced a uniform transfection of the treated volume, resulting in
a large area of transfected cells confined to the space between the
needle rows (Fig. 2a), with the majority of the transfected cells
concentrated around the panniculus carnosus muscle layer in the
deepest layer of the skin (Fig. 2c–e). Transfected cells were also
found in the hypodermis (Fig. 2c–e) and in sparse numbers
through the dermis and epidermis (Fig. 2e, f). However, no
expression was observed in actual muscle cells. No background
staining was seen in untreated skin (Fig. 2g) and neither luciferase
nor LacZ expression was detected in the tissue immediately below
the injected skin (data not shown). The data demonstrate that
intradermal DNA delivery in combination with electroporation
Figure 2. b-galactosidase expression in skin following DNA electrovaccination. Mice were injected intradermally with 20 ug DNA encoding
LacZ and the injection site was electroporated. (a, b) Skin biopsies were removed after 24 hrs and stained with X-gal (a); arrows indicate needle
penetration sites (b). (c–g) Distribution of b-galactosidase expressing cells in skin sections 24 hrs after DNA electrovaccination. Skin sections were
prepared for histochemistry and stained with X-gal; 4X (c, e, g) and 20X (d, f) magnifications of skin sections show b-galactosidase expressing cells
around the panniculus carnosus muscle layer (c–d) and in the hypodermis (c–e), dermis and epidermis (e, f). Untreated skin stained with X-gal was
used as a negative control (g). P=panniculus carnosus, H=hypodermis, D=dermis and E=epidermis.
doi:10.1371/journal.pone.0007226.g002
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yields faster, higher and more consistent gene expression,
compared to intradermal gene delivery alone.
Co-injection of an immunogenic antigen abolishes
long-term luciferase expression
To test whether the observed long-term expression of luciferase
is associated with its relatively low immunogenicity [25], the pVax-
luc plasmid was co-injected with plasmid pVax-PSA. The
hypothesis was that co-injection with prostate specific antigen
(PSA), which is highly immunogenic in mice [16], would cause a T
cell mediated immune attack on the PSA/luciferase transfected
cells and therefore result in elimination of luciferase expressing
cells. To confirm that PSA-specific CD8
+ T cells were induced by
the vaccination, blood was collected from the tail of mice after two
weeks and then the mice were kept for further luminescence
monitoring. In mice vaccinated with a combination of pVax-luc
and pVax-PSA, an average of 3.760.7% (SD) of the CD8
+ T cells
produced IFN-c in response to stimulation with a PSA-derived
peptide (Fig. 3a). No PSA-specific T-cells were detected when
electroporation was applied seconds before DNA injection
(supporting information Fig. S1). The background response
of T cells isolated from mice vaccinated with pVax-luc was less
than 0.1% (Fig. 3a). In vivo imaging analysis revealed that
luciferase gene expression did not differ between the groups during
the first 9 days after vaccination (Fig. 3b). At day 16, luciferase
expression had significantly dropped in mice co-injected with the
PSA expressing plasmid, following the appearance of PSA-specific
CD8
+ cells, and at day 21 the expression was below detection level
(Fig. 3b). In mice vaccinated with only pVax-luc, protein
expression was still high 60 days after vaccination (Fig. 3b). This
suggests that electrovaccination with an immunogenic antigen can
induce a cellular immune response capable of eliminating
transgene transfected cells.
Electroporation after intradermal DNA injection does not
result in increased plasmid persistence
To investigate whether electrovaccination affects not only gene
expression, but also the persistence of plasmid DNA at the
injection site, mice were injected either with 2, 10 or 50 mg pVax-
PSA plasmid followed by electroporation or with 50 mg pVax-PSA
alone. DNA injection sites were surgically removed 7, 30 or 60
days after DNA administration and the number of persisting
plasmid copies in the skin biopsies was determined using qPCR.
The group that was not subjected to electroporation had a higher
average number of plasmid copies at day 7 compared to mice
receiving the same dose followed by electroporation, though the
difference was not significant (Fig. 4). Plasmid persistence at day
30 or 60 after DNA administration did not differ between mice
that received 50 mg DNA by needle injection without electropo-
ration and mice receiving 50 mg DNA together with electropora-
tion (Fig. 4). Taken together, the results demonstrate that the
number of plasmids persisting in skin decreases over time and that
adding electroporation to intradermal DNA administration does
not significantly affect the number of persisting plasmid copies in
skin.
Electroporation results in local up-regulation of immune
regulatory genes
To investigate the effect of intradermal electroporation on the
skin microenvironment, a gene profiling study of the injection site
24 hrs after electrovaccination was performed. No visible
Figure 3. Effect of vaccine-specific T cells on transgene expression in skin. Mice were vaccinated with a combination of pVax-Luc/pVax-PSA
or pVax-Luc alone and were then analyzed for PSA-specific T cells and luciferase expression. (a) Representative flow cytometry dot plots showing
interferon-c producing CD8
+ T cells (upper right quadrant) in response to PSA peptide stimulation, pVax-Luc/pVax-PSA vaccination (upper panel) and
pVax-Luc vaccination (lower panel). (b) Time course of luciferase expression in skin. pVax-Luc alone (filled squares) or in combination with pVax-PSA
(filled triangles). Shown is mean6SD (n=9). The experiment was repeated three times.
doi:10.1371/journal.pone.0007226.g003
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electrovaccinated mice were observed. A gene array analysis
demonstrated that the combination of DNA injection and
electroporation compared to untreated skin caused an at least 2-
fold up- or down-regulation of 436 and 231 genes, respectively (not
shown). Based on several pre-processing approaches, a list of ,500
modulated genes (2 FC and ,5% FDR) was analysed using
Ingenuity. The highest ranked canonical signaling pathway was
the interferon pathway. A gene ontology search of the up-
regulated genes showed that among the most up-regulated gene
categories are defense responses, immune responses, responses to
biotic and external stimulus, inflammatory responses, chemotaxis
and MHC class I receptor activity (supporting information
Table S1). The 20 genes with the highest up-regulation (fold
change from 176-25, Table 1) included several that encode
proteins involved in immune regulation, such as chemokines,
markers of cellular (dendritic cells, T cells and keratinocytes)
activation, acute phase and proinflammatory molecules. To verify
the gene profiling results and to analyze the impact of the two
separate components of electrovaccination (DNA injection and
electroporation) on the skin microenvironment, skin was examined
from 1) untreated mice, 2) DNA injected mice, 3) electroporated
mice, and 4) mice that received DNA injection followed by
electroporation. A qPCR analysis of the following genes was
performed: Chemokine (CXC-motif) ligand 2 (Cxcl2), Interleukin
1 beta (IL-1b), Immunoresponsive gene 1 (Irg1), Matrix
metallopeptidase 13 (Mmp13), S100 calcium binding protein A9
(S100a9) and Chemokine (CC-motif) ligand 2 (Ccl2). Expression of
all the investigated genes was significantly higher (approximately
10-fold) in skin that had been treated with the combination of
DNA and electroporation than in skin that had got either
treatment alone (Fig. 5).
Discussion
The addition of electroporation to intradermally delivered DNA
leads to faster induction of transgene expression, increased levels of
produced antigen and up-regulation of genes involved in local
inflammatory and immune responses. At the same time, skin
electroporation does not increase the number of persisting plasmid
copies in skin compared to plasmid injection alone.
Our study shows that, using an in vivo imaging system, cells
expressing luciferase could be detected as early as 17 min after
electrovaccination, while expression of DNA delivered without
electroporation was still not detectable 1 hr after vaccination. In
similar studies exploring transgene expression in skin after non-
electroporative intradermal injection, expression was detectable
with an in vivo imaging system [26] 10 hrs after DNA
administration, and after 6 hrs using the more sensitive in vitro
detection assay [15]. By collecting and immediately freezing
muscle tissue after DNA injection, Doh et al. demonstrated that
luciferase expression could be detected in vitro as early as 30 min
post injection (in some mice already after 2 min) [27], showing
that even without electroporation, plasmids can be translated
within minutes after delivery. However, given a detection limit of
around 1000–5000 cells with in vivo imaging [28,29], detection of
luminescence within 20–30 min after intradermal electrovaccina-
tion in the present study suggests that an exceptionally high
number of transfected cells are producing protein shortly after
DNA injection. The 2-log increase in gene expression after dermal
electroporation in this study is consistent with previous results
[15,16].
Analysis of murine skin sections after DNA electroporation
demonstrated that most of the transfected cells were distributed
around the panniculus carnosus muscle layer and in the
hypodermis. The low number of transfected cells in the epidermis
and upper dermis could be a consequence of the difficulty of
injecting DNA in these thin skin layers of mice. However, similar
studies of intradermal DNA electrovaccination in mice, and larger
animal models such as rabbits and pigs, have also shown that the
Figure 4. Plasmid persistence in skin over time. Histogram
showing numbers of persisting plasmid copies at the indicated time-
points after intradermal DNA injection of the specified doses. Error bars
represent mean6SD (n=6 individual samples). Each individual sample
was analyzed in triplicate for each QPCR. The QPCR assay was run three
times. EP, electroporation.
doi:10.1371/journal.pone.0007226.g004
Table 1. Top 20 genes with highest up-regulation in
DNA+electroporation treated skin compared to untreated
skin.
Gene Symbol FC Gene Title
Gsta4 176.4 glutathione S-transferase, alpha 4
Clec4d 175.9 C-type lectin domain family 4, member d
Cxcl2 141.6 chemokine (C-X-C motif) ligand 2
Krt2-6b 99.1 keratin complex 2, basic, gene 6b
Ccl5 97.9 chemokine (C-C motif) ligand 5
Saa3 62.7 serum amyloid A 3
Il1b 47.5 interleukin 1 beta
Cxcl5 41.6 chemokine (C-X-C motif) ligand 5
Il1rl1 40.9 interleukin 1 receptor-like 1
Spp1 39.2 secreted phosphoprotein 1
Irg1 37.5 immunoresponsive gene 1
Chi3l3 33.4 chitinase 3-like 3
Cxcl9 33.3 chemokine (C-X-C motif) ligand 9
Mmp13 31.4 matrix metallopeptidase 13
Slfn3 ///Slfn4 30.3 schlafen 3 /// schlafen 4
Cxcl1 29.5 chemokine (C-X-C motif) ligand 1
Anked1 28.8 ankyrin repeat domain 1 (cardiac muscle)
Rsad2 27.4 radical S-adenosyl methionine domain containing 2
S100a9 25.7 S100 calcium binding protein A9 (calgranulin B)
Cxcl10 25.5 chemokine (C-X-C motif) ligand 10
Ccl2 24.6 chemokine (C-C motif) ligand 2
FC, fold change.
doi:10.1371/journal.pone.0007226.t001
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subdermal tissues [15,30,31,22]. The transfected cells include
adipocytes, fibroblasts, endothelial cells and numerous mononu-
clear cells with dendritic processes [32]. A different approach,
where DNA was applied topically and delivered into murine skin
by a tattoo device, demonstrated the presence of transfected cells
in both the epidermis and the upper dermis. In contrast to
electroporation, tatooing led to a transient b-galactosidase
expression, which disappeared over the first 4 days; induction of
vaccine specific T cells required three vaccinations within 6 days
[33].
In the present study, transgene expression remained high after
60 days and was still detectable after 5 months (data not shown).
As the luciferase protein only has a half-life of 3–4 hrs in
mammalian cells [34] the detection of luciferase is most probably a
result of continuously expressed protein from the plasmid and not
of lingering protein expressed months earlier. This long-term
expression is not unexpected since others have reported that
luciferase is a relatively non-immunogenic protein [25] and its
expression can last for 19 months in vivo even without
electroporation [35]. We therefore mixed luciferase DNA with
DNA encoding the more immunogenic prostate specific antigen
(PSA) to investigate whether this would affect clearance of DNA
transfected cells. We have previously shown that after PSA
electrovaccination in mice, PSA-specific CD8
+ T cells are
detectable in peripheral blood at day 11 and peak around day
13 [16]. The gradual clearance of luciferase expression between
days 9 and 21 in skin of mice receiving a DNA mixture of
luciferase and PSA demonstrates a temporal association between
the induction of PSA-specific T cells and the disappearance of cells
expressing luciferase. Therefore our data suggest a role for T cells
in limiting vaccine antigen expression and indicate that the long-
term expression of luciferase is most probably a feature of its low
immunogenicity. This hypothesis is further supported by data
published by Widera et al., showing unchanged protein expression
in immunodeficient mice as opposed to waning expression of a
transgene by day 13 in immunocompetent mice [4]. Others
confirm these results by demonstrating that loss of vaccine antigen
expression in muscle cells became apparent approximately
cotemporaneously with the initial detection of antigen-specific T
cells to the same immunogen and that persistent vaccine antigen
expression was associated with poor vaccine immunogenicity [36].
The elimination of vaccine antigen expressing cells might be
especially important for immunotherapy applications, where a
long-term, stable expression of the transgene could cause
unwanted tolerance. Improvement of the immunogenicity of the
vaccine by co-delivery of helper epitopes [2,37], xenogenic
approaches [38,39], optimized delivery techniques [2,40] and/or
use of adjuvants [40–42] is therefore desirable for the generation of
robust immunity, while for other applications, such as gene
therapy, a long-term, stable expression of the transgene might be
beneficial.
The DNA persistence data show that even though luciferase
expression is not detectable by in vivo imaging 21 days after PSA/
luc vaccination, PSA DNA is revealed by PCR at the injection site
60 days after vaccination. This difference might partly be due to
the sensitivity of the detection technologies. However, the results
might also indicate that cells actively expressing PSA are
eliminated while the persisting PSA DNA seen at day 60, could
be from cells with extranuclear or intranuclear but transcription-
ally inactive plasmid (or parts of plasmids), i.e. from cells
containing PSA DNA but that are not expressing the PSA protein.
Since the immune response determines the prolonged existence of
the antigen expression, it is also possible that multiple vaccinations
(boosting inoculations) would have led to a more rapid decline and
lower persistence of plasmid copies, especially for the less
immunogenic luciferase plasmid. Many pre-clinical studies have
shown that electroporation dramatically increases the immune
response to DNA vaccines, and several phase I/II trials are
currently evaluating electrovaccination in patients [7,43]. How-
ever, since electroporation significantly increases the transgene
expression and this probably is due to a higher cellular uptake of
DNA molecules, safety-related questions have been raised about
the possibility that electroporation could lead to increased DNA
persistence and a higher integration frequency [7,17]. Our results
demonstrate a 100-fold increase in antigen expression, but no
increase in DNA persistence, after intradermal electroporative
DNA delivery. This concurs with recent reports that intramuscular
electroporation did not lead to increased plasmid persistence
[12,11]. Studies investigating integration events were not per-
formed after immunization with the PSA plasmid. However, in a
parallel study, in which plasmid DNA [44] vectoring viral genes
were delivered by electroporation (Cyto Pulse Sciences), we have
noted a considerable decrease in plasmid DNA in the skin during
Figure 5. Genes up-regulated at the DNA electrovaccination site. Histogram showing fold increase in gene expression, compared to non-
treated control skin, of the indicated genes after the specified treatments. Bars represent mean6SD. The number of independently analyzed samples
varied from 4–6; and each sample was run in duplicates or triplicates for each QPCR. The QPCR analysis was run three times.
doi:10.1371/journal.pone.0007226.g005
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Gel Electrophoresis (FIGE), separating the chromosomal DNA
from plasmid DNA, a 3 log reduction in plasmid copy number was
observed. After the second round of FIGE, the plasmid DNA
associated with the genomic DNA was either below the limit of
detection (,10 copies/ug genomic DNA) or not quantifiable
(,100 copies/ug genomic DNA) as determined by Q-PCR
(manuscript in preparation). Furthermore, another study demon-
strated that intramuscular electroporation did not result in an
increase in plasmid DNA associated with high molecular weight
DNA, relative to macaques receiving plasmid DNA without
electroporation [11]. However, a study by Wang et al. reported on
the contrary that intramuscular electroporation did lead to higher
levels of plasmid DNA persistence and increased plasmid DNA
integration into chromosomal DNA compared to DNA delivery
without electroporation [13]. Nevertheless, the frequency of
integration was at least 3 orders of magnitude below the
spontaneous rate of gene-inactivating mutations [13].
The gene profiling of the treatment site identified several genes
encoding proteins involved in immune regulation (such as
chemokines, markers of cellular activation, acute phase and
proinflammatory molecules) as being highly up-regulated follow-
ing electrovaccination. The fact that electroporation alone up-
regulated several immune/inflammatory related genes supports
previous data by others suggesting that electroporation has an
adjuvant effect in addition to the increased transfection efficiency
[19]. Specifically, the high up-regulation of several chemokines
(CXCL2, CCL5, CXCL5, CXCL9, CXCL1 CXCL10) which
control the recruitment of leukocytes to the vaccination site is
important for the early phases of the immune response [45]. The
dramatic up-regulation of glutathione S-transferase (Gsta4), serum
amyloid A3 (Saa3), S100a9 and IL-1b further indicates the
presence of an inflammatory response [46]. Genes indicating an
increased DC presence (Clec4d, IL-1b) [47] and activation
(Mmp13) [47] were also up-regulated, which might potentiate
the immune response. Even though the gene profiling data support
the hypothesis that electroporation has an adjuvant effect, no
induction of PSA-specific T cells was detected when electropora-
tion was applied seconds before the DNA injection.
In summary, the addition of electroporation to intradermally
delivered DNA leads to faster induction of transgene expression,
increased levels of produced antigen and up-regulation of genes
involved in local inflammatory and immune responses. Further-
more, application of electroporation after administration of DNA
does not increase the number of persisting plasmid copies in skin
compared to plasmid injection alone. The information provided in
this study is valuable for bringing intradermal electroporation
closer to clinical evaluation.
Materials and Methods
Animals
Balb/c and C57Bl/6 mice (6–10 wk old) were bred and housed
at the animal facility of the Microbiology and Tumor Biology
Center at the Karolinska Institutet, Stockholm, Sweden. Mice
were anesthetized with 4% isoflurane (Baxter Medical AB, Kista,
Sweden) and anaesthesia was maintained at 2–2.5% isoflurane in
masks during all intradermal injections, electroporations and live
imaging. All experiments using mice were approved by the
Swedish National Board for Laboratory Animals.
Plasmids
The luciferase-encoding plasmid, pVax-luc, and plasmid pVax-
PSA encoding prostate specific antigen, have been described
previously [16]. The pVax-LacZ plasmid was purchased from
Invitrogen (Carlsbad, CA, USA). Plasmids were amplified in E.
Coli and purified using an Endotoxin Free Plasmid Purification Kit
(QIAGEN, Hilden, Germany). The DNA was dissolved in sterile
PBS.
DNA injections and in vivo electroporation
Intradermal injections in mice (10–50 mg DNA/20 ml PBS)
were made near the base of the tail using a 29 G insulin grade
syringe (BD Consumer Healthcare, Franklin Lakes, NJ). Immedi-
ately after DNA administration, an electrode was placed over the
injection site and voltage was applied (2 pulses, 1125 V/cm,
50 msec+8 pulses, 275 V/cm, 10 msec). Electrodes had two
parallel rows of four 2-mm pins (1.564 mm gaps) (Cyto Pulse
Sciences, Inc., Glen Burnie, MD). Electroporation was performed
using the PA-4000S-Advanced PulseAgileH Rectangular Wave
Electroporation System (Cyto Pulse Sciences, Inc.).
Live imaging of protein expression after DNA vaccination
After DNA injection, mice were injected intraperitoneally with
100 ml/10 g mouse body weight of a 15 mg/ml solution of D-
luciferin potassium salt (Xenogen, Alameda, CA) in PBS.
Assessment of photonic emissions using the In Vivo Imaging
System 100 (Xenogen) was performed 20 min after injection of D-
luciferin. Overlay of images and luminescence measurements were
made using Living Image software (version 2.50.1; Xenogen). A
region of interest (ROI) was manually selected over the signal
intensity. The area of the ROI was kept constant for all DNA
injection sites and the intensity of luminescence (photons/sec/cm
2)
was recorded within the ROIs. Background luminescence
(,200 pixels/sec/cm
2) was determined by measuring lumines-
cence from mice injected with empty vector DNA (pVAX1)
followed by electroporation. For imaging of immediate protein
expression, substrate (30 mg/ml D-luciferin) was injected 10 min
before DNA injection. Assessment of photonic emissions was
started immediately after DNA vaccination.
b-galactosidase expression
Skin biopsies were removed from female C57Bl/6 mice 24–
72 hours after LacZ DNA injection and electroporation. For
expression in whole skin, the biopsies were fixed in 4%
paraformaldehyde for 3 hours. To detect b-galactosidase activity,
the biopsies were incubated in 1 mM X-gal (Invitrogen) at 37uC
for 18 hours. For detection of b-glactosidase expression in sections,
the biopsies were embedded in OCT; 10 mm sections were fixed in
acetone/methanol (50/50) for 10 minutes and subsequently
incubated in 1 mM X-gal for 3 hours. Sections were counter-
stained with eosin and mounted.
Analysis of IFNc-producing vaccine-specific CD8
+ T cells
C57Bl/6 mice were injected intradermally on both flanks with
either 10 mg pVax-luc alone or combined with 10 mg pVax-PSA,
followed by electroporation. On day 13 after vaccination, 100 ml
blood was collected from the tail vein and cells were stained for
intracellular IFN-c production after a 4 hr stimulation with a PSA
derived peptide, as previously described [16]. Samples were
analyzed using a FACSCalibur flow cytometer (Becton Dickinson)
and CELLQuest software (Becton Dickinson).
DNA persistence in skin – DNA purification and
quantitative PCR (qPCR)
Balb/c mice were injected intradermally either with 2, 10 or
50 mg pVax-PSA followed by electroporation or with 50 mg pVax-
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after injection and the DNA injection sites were surgically removed.
The skin biopsies were stored at 280uC until homogenization.
Homogenization and total DNA extraction were performed using
the DNeasy Blood & Tissue Kit (QIAGEN) according to the
manufacturer’s instructions. The purified DNAwas eluted in 200 ml
nuclease-free water (Applied Biosystems, Foster City, CA, USA).
The level of plasmid DNA was determined using absolute
quantification by qPCR (7500 Real-Time PCR System; Applied
Biosystems) according to the manufacturer’s instructions with the
following PSA-specific primers and probe: 59-ttgtcttcctcaccctgtcc-39
(forward primer), 59-tcacgcttttgttcctgatg-39 (reverse primer), 59-
FAM-ctcatcctgtctcggattgtg-TAMRA-39 (probe). The oligonucleo-
tides were purchased from MedProbe (Lund, Sweden) and were
used at a final concentration of 300 nM. The qPCR was optimized
using standard protocols and the limit of detection of the assay was
10 plasmid copies. The number of plasmid copies per mg genomic
DNA was determinedusinga standard dilution curve of the plasmid
in genomic murine DNA. All skin biopsies were processed and
analyzed independently.
RNA isolation and gene expression profiling
C57Bl/6 mice were intradermally injected with 10 mg pVax-
PSA followed by electroporation or left untreated. Mice were
sacrificed 24 hrs later and the DNA injection sites and control sites
were surgically removed. Immediately thereafter, the skin biopsies
were snap frozen in liquid nitrogen and stored at 280uC until
RNA isolation. The biopsies were homogenized (Polytron,
Kinematica) in 1 ml TRIzol (Invitrogen) and total RNA was
isolated according to the manufacturer’s protocol. All skin biopsies
were processed and analyzed independently. The size of the tissues
ranged from 45–60 mg. Total RNA was dissolved in 30 ml RNase-
free water. Typically, the yield was 40–50 mg of total RNA from
50 mg of tissue. RNA quality was confirmed by analysis in an
Agilent 2100 Bioanalyser (Agilent Technologies, Inc, Paolo Alto,
CA, USA) and quantified using a Nanodrop. cRNA synthesis and
hybridization to U74v2 GeneChipH arrays was done according to
the protocol recommended by the manufacturer (Affymetrix Inc.,
Santa Clara, CA, USA). CEL-files were imported from Affymetrix
GeneChipH Operating Software (GCOS), and summary values
created using MAS5. Analysis was carried out between the two
experimental groups (untreated mice (n=4), and mice subjected to
DNA vaccination followed by electroporation (n=3)) using
significance analysis of microarrays (SAM) [48] which estimates
the false discovery rate (FDR). Lastly, a fold change value for
treated compared with untreated skin (control) gene expression
was applied using the mean of the four replicates for each group.
Thus, genes with an FDR of ,5% and a mean expression that was
at least twofold up- or down-regulated from baseline were
considered further. The regulated gene list was consistent with
both MAS5 and RMA normalisation (data not shown). For the
pathway analysis we utilized a list of ,500 genes (up- and down-
regulated) from the MaS5 and SAM analysis. Pathway analysis
was carried out using the web-based bioinformatics tool, Ingenuity
pathway analysis (IPA, http://www.ingenuity.com). Affymetrix
probe set IDs were uploaded into IPA and queried against all
other genes stored in the IPA knowledge database. Probe sets
representing genes having direct interactions with genes in the IPA
knowledge database are called ‘‘focus’’ genes, which were then
used as a starting point for generating functional networks. Each
generated network is assigned a score according to the number of
differentially regulated focus genes in our dataset. This identified
significant canonical pathways, and gene expression changes were
annotated using the FC values from the SAM analysis. It should be
noted, however, that while the database extends the interpretation
beyond mRNA transcript levels (as network genes do not have to
be differentially expressed at the mRNA level), the data reflect
current knowledge. The raw data files are available at Gene
Expression Omnibus (GEO) under data set reference GSE18003.
Validation of gene array results by qPCR
C57Bl/6 mice were either intradermally injected with 10 mg
pVax-PSA followed by electroporation, injected with 10 mg pVax-
PSA without electroporation, electroporated only, or left untreat-
ed. 24 hrs later the treatment site was excised and total RNA from
skin biopsies was extracted as described above and reverse
transcribed using TaqManH Reverse Transcription Reagents
(Applied Biosystems). All skin biopsies were processed and
analyzed independently. Detection of mRNA was performed
using a 7500 Real Time PCR System (Applied Biosystems).
Primers were designed using ProbeFinder version 2.35 for the
Mouse Universal ProbeLibrary (http://www.universalprobelibrary.
com) from Roche Applied Science and were purchased from
MedProbe (primer sequences are listed in the supporting
information Table S2). A pre-optimized primer and probe
assay for 18S rRNA (Applied Biosystems) was used as an
endogenous control. Primers (300 nM final concentration) were
pre-mixed with SYBRHGREEN PCR Master Mix (Applied
Biosystems) and applied to 96-well MicroAmp Optical plates
(Applied Biosystems). Skin cDNA aliquots were diluted 1:10 and
3 ml were added in triplicates. Skin cDNA diluted 1:500 was used
for detection of 18S rRNA. Samples were assessed for DNA
contamination by including cDNA controls prepared without
reverse transcriptase. Standard thermal cycling conditions were
applied. For calculation of fold changes of target gene expression
between different treatment schedules, the DDCt-method was
applied as previously described [49]. The threshold cycle (CT) for
18S was subtracted from the CT for the target gene to adjust for
variations in the cDNA synthesis.
Statistics
Two-way ANOVA analysis was used to investigate differences
in luciferase transgene expression between mice receiving
electroporation or not. DNA persistence data were analyzed using
2-way ANOVA, where dose/time and electroporation/time were
used as variables. Statistical differences in plasmid persistence
between groups at day 60 were analyzed using the non-parametric
Kruskal-Wallis test. Quantitative PCR data were analyzed using
the 2
2DDCT method. Normality of q-PCR data was tested using
the D’Agostino & Pearson omnibus normality test. As data did not
pass the normality test, Kruskal-Wallis tests were used to analyze
the impact of treatment on gene expression. P,0.05 was
considered statistically significant. All statistical analyses were
performed using GraphPad Prism version 4.03 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.
com.
Supporting Information
Figure S1 C57Bl/6 mice were injected intradermally on both
flanks with 10 mg pVax-PSA. The vaccination site were either not
electroporated (+DNA, -EP), electroporated after DNA adminis-
tration (+DNA, +EP) or electroporated before DNA injection
(+EP, +DNA). On day 13 after vaccination, spleens were harvested
and cells were stained for intracellular IFN-c production after a
4 hr stimulation with a PSA derived peptide, as previously
described [16].
Found at: doi:10.1371/journal.pone.0007226.s001 (0.03 MB TIF)
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